Mustang Bio (MBIO) Q1 2025 earnings summary

Executive summary

• Clinical-stage biopharma focused on CAR T therapies for hematologic malignancies, autoimmune diseases, and solid tumors, with partnerships at leading research institutions.

• No product sales to date; substantial operating losses since inception and expectation of continued losses.

• Substantial doubt exists about ability to continue as a going concern; recent cost reductions and asset sales to preserve capital.

• Regained compliance with Nasdaq listing requirements after a reverse stock split and equity offering.

Financial highlights

• Net loss for Q1 2025 was $0.2 million, a 97% improvement from $5.2 million in Q1 2024, mainly due to cost reductions and a gain on lease termination.

• Research and development expenses were negative $1.0 million (reflecting credits/gains), down from $3.8 million in Q1 2024.

• General and administrative expenses decreased to $1.2 million from $1.4 million year-over-year.

• Cash and cash equivalents at March 31, 2025, were $14.2 million, up from $6.8 million at year-end 2024, driven by equity financings and asset sales.

• Accumulated deficit reached $396.9 million as of March 31, 2025.

Outlook and guidance

• Expects to continue incurring significant operating losses and negative cash flows; will require substantial additional financing to fund operations and clinical development.

• Substantial doubt remains about ability to continue as a going concern for the next 12 months.

• Planning to initiate new investigator-sponsored clinical trials in 2026, contingent on additional funding.